New funding opportunity 🚨
National Cancer Institute (NCI) Division of Cancer Biology (DCB) has published FY26 Topics of Interest for Administrative Supplements.
Check details here:
www.cancer.gov/about-nci/or...

At today’s #ARTNetSCMeeting, Dr. Alan Hutson shared network updates and warmly welcomed new associate member Dr. Jennifer Wargo.
Dr. Yu-Ting Chou presented on “Deciphering the interplay of β-catenin/YAP signaling and alveolar lineage plasticity during targeted therapy in #NSCLC.”

Venetoclax and Palbociclib in AML: Exploring New Findings Despite recent treatment advances, most patients with acute myeloid leukemia (AML)—especially those ineligible for intensive chemotherapy—ultimately relapse due to adaptive resistance to therapies lik...

Venetoclax and Palbociclib in AML: Exploring New Findings reachmd.com/programs/on-...

At today's Cell States, Metabolism & Inflammatory Microenvironment #ARTNetWGMeeting, Dr. Teresa Zimmers of Oregon Health & Science University presented on “Cancer Cachexia and Treatment Resistance,” sparking a lively and engaging discussion.

🚨 Registration Now Open!
Join the Embedding Databases Workshop and help shape the future of AI-driven cancer research.
📅 Session A: April 8, 12:30–2:00 PM ET
📅 Session B: April 9, 2:00–3:30 PM ET
apply.knowinnovation.com/ai-embedding... #AI #DataScience #HealthData

Pan-RAF inhibitor exarafenib targets BRAF class II/III NSCLC and reveals ARAF-KSR1 resistance and combination strategies - Nature Communications While therapies targeting type I BRAF mutations have been developed, there are limited options for those with type II and III mutations. Here, the authors identify a subset of BRAF-mutant non-small ce...

New #ARTNetPublication:
A study by Dr. Trever Bivona and colleagues reveals that the pan-RAF inhibitor exarafenib shows strong activity against BRAF Class II/III NSCLC, a population with no approved targeted therapies and representing ~65% of BRAF-mutant cases.
Read more: doi.org/10.1038/s414...

Temporal photoproximity labeling of ligand-activated EGFR neighborhoods using MultiMap - PubMed Photoproximity labeling proteomics (PLP) methods have recently shown that cell surface receptors can form lateral interactome networks. Here, we present a paired set of PLP workflows that dynamically track neighborhood changes for oncogenic epidermal growth factor receptor (EGFR) over time, both out …

New #ARTNetPublication introduces MultiMap, a temporal photoproximity labeling approach to track dynamic EGFR interaction neighborhoods in real time.
pubmed.ncbi.nlm.nih.gov/41254216/

At today’s #ARTNetSCMeeting, Dr. Alan Hutson provided network updates. Drs. Eric Knudsen and David Goodrich of @roswellpark.bsky.social presented the WG white paper proposal.
Dr. Ann-Kathrin Eisfeld of OSU spoke on leveraging constitutional genetic diversity to increase knowledge about AML biology.

At today’s Functional Screens & Assay Development #ARTNetWGMeeting, Dr. Molly Ingersoll of @InstitutCochin presented “Mucosal Immunity and Challenges in Treating UTI,” triggering lively discussion.

At today's Cell States, Metabolism & Inflammatory Microenvironment WG Meeting, Dr. Dannielle Engle of Salk Institute for Biological Studies shared her work on glycan-driven rewiring of the pancreatic tumor microenvironment.

Congrats to all the authors! #ARTNetPublication

Kudos to all the authors!🎉

At today’s #ARTNetSCMeeting, Dr. Alan Hutson provided network updates. Drs. Shannon McWeeney and Daniel Bottomly highlighted a newly published study in Scientific Data, a collaborative effort across the ARTNet Consortium.
Read the paper:
www.nature.com/articles/s41...

#ARTNetPublication A new paper in Nature Comms by Dr. Trever Bivona shows that exarafenib, a pan-RAF inhibitor, has strong activity against BRAF Class II/III NSCLC, mutations that make up ~65% of BRAF-mutant cases and currently lack approved therapies.
www.nature.com/articles/s41...

🧬 CIP-Net Project Spotlight
UG3CA290454 is developing a preventive cancer vaccine for people with inherited BRCA1/2 mutations, using chimeric RNA-derived neoantigens to stop breast cancer before it forms.
👉Learn more on the CIP-Net website: www.nci-cipnet.org/en/members/u...

At today's Cell State, Metabolism & Inflammatory Microenvironment #ARTNetWGMeeting, Dr. Nina Grace Steele of University of Cincinnati presented on extracting mechanisms of cellular talk in pancreatic acancer using big data,sparking a lively and engaging discussion.

Registration for the NCI CAP-IT Annual Summit: March 30, 2026 The upcoming NCI CAP-IT Summit is set to convene a diverse mix of participants, including senior leaders, experts, and emerging talents such as junior investigators and trainees, all dedicated to the ...

Save the date! The #CAPITSummit is happening on March 30, 2026.
A full day of science, strategy, and community—bringing together researchers, clinicians, and advocates to advance cancer prevention and interception.
Register now and join us:
tinyurl.com/5c6snwyz

Temporal photoproximity labeling of ligand-activated EGFR neighborhoods using MultiMap - PubMed Photoproximity labeling proteomics (PLP) methods have recently shown that cell surface receptors can form lateral interactome networks. Here, we present a paired set of PLP workflows that dynamically track neighborhood changes for oncogenic epidermal growth factor receptor (EGFR) over time, both out …

New #ARTNetPublication: Using paired photoproximity labeling (PLP) workflows, researchers dynamically mapped EGFR signaling neighborhoods inside and outside cells, capturing interactome changes within minutes to hours after EGF stimulation.
pubmed.ncbi.nlm.nih.gov/41254216/

For the scientific presentation, Dr. Ying Huang, from Dr. Michael Hollingsworth’s PCAC U54 team at UNMC, discussed how EV-mediated metabolic reprogramming by MUC1 promotes chemotherapy resistance, sparking a lively discussion. (2/2)

At today’s #ARTNetSCMeeting, SC Co-Chair Dr. Alan Hutson of @roswellpark.bsky.social shared network updates and welcomed our new associate member, Dr. Ann-Kathrin Eisfeld of @ohiostatepress.bsky.social . (1/2)

NSD2 targeting reverses plasticity and drug resistance in prostate cancer - PubMed Lineage plasticity is a cancer hallmark that drives disease progression and treatment resistance^1,2. Plasticity is often mediated by epigenetic mechanisms that may be reversible; however, there are few examples of such reversibility. In castration-resistant prostate cancer (CRPC), plastic …

Lineage plasticity fuels drug resistance in prostate cancer but it may be reversible.
This study in Nature shows targeting the histone methyltransferase NSD2 reverses plasticity in castration-resistant prostate cancer.
pubmed.ncbi.nlm.nih.gov/41299174/

Drug resistant cancer cells show increased nuclear mechanotransduction and mechanically targetable YAP-regulated vulnerability - PubMed Drug resistance is a leading cause of cancer treatment failure and tumor recurrence. Identifying new methods that eliminate life-threatening drug-resistant cancer cells (DRCs) can enhance tumor cell eradication and improve patient outcomes. Here we report that human non-small cell lung cancer (NSCLC …

Drug-resistant NSCLC cells harbor an unexpected vulnerability: heightened mechanosensitivity.
Read this #ARTNetPublication by Dr. Trever Bivona, from the ARTNet BAATAAR-UP U54 at UCSF.
pubmed.ncbi.nlm.nih.gov/41443038/

At today’s #ARTNetSCMeeting, Dr. Heather Lankes introduced NCTN Biobanks: nctnbanks.cancer.gov.
Dr. Stephen Lai of H-CARR U54 @mdanderson.bsky.social shared updates on their research quantifying cisplatin sensitivity and resistance using metabolic imaging and circulating tumor cell (CTC) biomarkers.

Discover novel IO targets and biotherapeutics! Attend tomorrow's AI, Upcoming Technologies, and Potential Applications #webinar to gain valuable insights for predicting patient responses to immunotherapy. Learn more and register: https://ow.ly/R6Uq50XA2uX

At today's #ARTNetSCMeeting, Dr. Sohail Tavazoie of
@rockefeller.edu presented his research on the regulation of #metastasis.

Join SITC and NCI for the Computational Immuno-oncology Webinar Series Course 9: Using Spatial Biology to Monitor Tumor Immune Interactions on Nov. 13, 2025 (1–2 p.m. ET).

Register for this free digital event: sitcancer.org/CompIO

Dr. Sandulache is MPI of the #ARTNet H-CARR center 👏👏
This #VeteransDay the NRG Oncology podcast co-hosts sit with NRG Veteran Affairs-Military Treatment Facility Subcommittee Chair Vlad Sandulache to discuss the subcommittee and their goals + clinical research at VA sites. nrgoncology.org/Podcast

New paper in Immunity: Myeloid cells mediate interferon-driven resistance to immunotherapy in advanced renal cell carcinoma
t.co/RswnD7TE2s

The latest issue of the #ARTNet Newsletter is out!
It features highlights and reports from the ARTNet Scientific Retreat held in September 2025, along with updates on network progress and ongoing initiatives. indd.adobe.com/view/9af991c...

Cancer-associated nerve injury leads to chronic inflammation and immunotherapy resistance Cancer-associated nerve injury leads to chronic inflammation and immunotherapy resistance

ARTNet investigator Dr. Moran Amit of @mdanderson.bsky.social report in Nature that cancer cells can damage protective nerve coverings, causing nerve injury and chronic inflammation.These injuries drive immune exhaustion and immunotherapy resistance.
tinyurl.com/y3pk453e